In recent years, the use of oral direct-acting antiviral (DAA) agents and antiretroviral therapies (ART) with improved efficacy and tolerability has changed the treatment landscape in patients with HIV/HCV coinfection. Nonetheless, the optimal management of liver-related morbidity and progressive liver disease remains a critical challenge that warrants special consideration. In this interactive, case-based eCourse, two experts review current guideline recommendations and evidence-based strategies for diagnosing, monitoring, and managing patients with HIV/HCV coinfection. Other key topics of discussion include the epidemiology of and risks associated with HIV/HCV coinfection, the efficacy and safety of DAAs in clinical trial and real-world settings, assessment for reinfection, and preserving the benefits of HCV cure in high-risk patient populations.
Interactive, audio-enhanced slide lecture
After completing this activity, participants should be better able to:
- Describe evidence for DAA sustained virologic response rates in coinfected and monoinfected patient populations and current AASLD/IDSA guidelines for treating coinfected patients
- Select DAA/ART regimens that minimize drug‐drug interactions and toxicities, support adherence, and consider patient and systemic factors
- Apply guideline‐recommended strategies for the long‐term management of HIV/HCV coinfected patients
NPs and PAs
CNE Credit Designation
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
AAPA Credit Designation Statement
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until May 1, 2020. PAs should only claim credit commensurate with the extent of their participation.
PA Planner: Richard H. Davis, Jr, PA-C
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from AbbVie Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any significant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr. Reau: advisory board: Abbott, AbbVie, Gilead, Merck; research/grant support: Genfit, Intercept, Shire.
Dr. Kwong: speakers bureau: Gilead.
None of the members of the Planning Committee or independent reviewer have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Watch the ecourse in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: May 1, 2019
Expiration date: May 1, 2020
© 2020 Practicing Clinicians Exchange. All Rights Reserved. APCE95919